C Elkins Ronald Sells 10,000 Shares of CryoLife (CRY) Stock

CryoLife (NYSE:CRY) Director C Elkins Ronald sold 10,000 shares of CryoLife stock in a transaction that occurred on Monday, May 14th. The stock was sold at an average price of $24.75, for a total value of $247,500.00. Following the completion of the sale, the director now directly owns 78,997 shares in the company, valued at $1,955,175.75. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

C Elkins Ronald also recently made the following trade(s):

  • On Thursday, May 10th, C Elkins Ronald sold 6,852 shares of CryoLife stock. The stock was sold at an average price of $25.38, for a total value of $173,903.76.
  • On Thursday, March 8th, C Elkins Ronald sold 2,000 shares of CryoLife stock. The stock was sold at an average price of $22.00, for a total value of $44,000.00.

NYSE CRY opened at $25.95 on Thursday. The firm has a market cap of $937.79 million, a price-to-earnings ratio of 64.88 and a beta of 0.73. The company has a current ratio of 5.07, a quick ratio of 3.72 and a debt-to-equity ratio of 0.77. CryoLife has a fifty-two week low of $25.95 and a fifty-two week high of $27.10.

CryoLife (NYSE:CRY) last released its quarterly earnings data on Wednesday, May 2nd. The medical equipment provider reported $0.02 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.02. The company had revenue of $61.95 million for the quarter, compared to analyst estimates of $60.30 million. CryoLife had a positive return on equity of 4.55% and a negative net margin of 1.15%. The firm’s revenue for the quarter was up 37.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.09 earnings per share. equities analysts anticipate that CryoLife will post 0.3 EPS for the current year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN raised its stake in CryoLife by 53.0% in the 3rd quarter. Wells Fargo & Company MN now owns 47,904 shares of the medical equipment provider’s stock worth $1,087,000 after purchasing an additional 16,591 shares in the last quarter. California Public Employees Retirement System raised its stake in CryoLife by 6.6% in the 3rd quarter. California Public Employees Retirement System now owns 95,172 shares of the medical equipment provider’s stock worth $2,160,000 after purchasing an additional 5,872 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in CryoLife by 4.4% in the 4th quarter. Schwab Charles Investment Management Inc. now owns 178,618 shares of the medical equipment provider’s stock worth $3,421,000 after purchasing an additional 7,529 shares in the last quarter. Monarch Partners Asset Management LLC raised its stake in CryoLife by 24.9% in the 4th quarter. Monarch Partners Asset Management LLC now owns 22,730 shares of the medical equipment provider’s stock worth $435,000 after purchasing an additional 4,530 shares in the last quarter. Finally, Teacher Retirement System of Texas acquired a new stake in CryoLife in the 4th quarter worth about $197,000. 67.67% of the stock is currently owned by institutional investors.

A number of analysts have recently issued reports on the company. Zacks Investment Research raised CryoLife from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Northland Securities reaffirmed a “buy” rating and issued a $23.50 price target on shares of CryoLife in a research note on Thursday, March 8th. Canaccord Genuity reaffirmed a “buy” rating and issued a $28.00 price target (up from $25.00) on shares of CryoLife in a research note on Friday, March 9th. Finally, ValuEngine lowered CryoLife from a “hold” rating to a “sell” rating in a research note on Wednesday, March 7th. Two analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. CryoLife currently has a consensus rating of “Hold” and a consensus price target of $26.63.

CryoLife Company Profile

CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.

Insider Buying and Selling by Quarter for CryoLife (NYSE:CRY)

Receive News & Ratings for CryoLife Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CryoLife and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply